

THOMAS JOSEPH RUTHERFORD
University of South Florida
Department of Obstetrics and Gynecology
2 Tampa General Circle, 6th floor
Tampa, FL 33606
(813) 259-8527
tjrutherford@.usf.edu

EDUCATION

- 1985 - 1989 Medical College of Ohio at Toledo
Arlington Ave.
Toledo, Ohio
M.D. (1989)
- 1979 - 1985 Medical College of Ohio at Toledo
Arlington Ave.
Toledo, Ohio
Ph.D. - Molecular Biology (1986)
- 1977 - 1979 John Carroll University
Cleveland, Ohio
M.S. - Chemistry (1983)
- 1976 - 1977 State University of New York at Buffalo
Buffalo, New York
- 1972 - 1976 Roanoke College
Salem, Virginia
B.S. - Chemistry (1976)

HONORS/AWARDS/SOCIETIES

- 1/94 - 6/95 American Cancer Clinical Oncology Fellowship
Alpha Omega Alpha, Honor Medical Society
Tau Sigma Rho Mathematics Honorary Society
Phi Delta Epsilon Medical Fraternity
Pi Kappa Phi Fraternity, President 1976
American College of Ob/Gyn
Society of Gynecologic Oncologists
New England Association of Gynecologic Oncologists

1995	1995 New England Association Gynecologic Oncologists Trainee Award
5/96 - present	American Medical Association
5/96	Cigna Oncology Steering Committee
8/96	Anthem BC/BS Oncology Panel
5/98 – 5/04	SGO Government Relations Committee
2000	Strathmore's Who's Who
1/01 - present	SGO Finance Committee
6/01 - present	International Society for the Study of Trophoblastic Disease
2/02 - present	Reviewer, State of CT, Department of Public Health
1/02 – 1/05	SGO Coding Committees
6/02	Guide to Americas Top Obstetricians and Gynecologist
2/04 – present	Director of Gynecologic Fellowship
8/04 – present	Madison Who's Who
10/05 –6/30/2014	Division Director of Gynecologic Oncology
1/10 – 2/5/15	Consultant – Gastrointestinal Drugs Advisory Committee, FDA
9/25/2013	Sanqin Friendship Award – Shaanxi Province
6/2014	Top Doctors – Castle Connolly Medical LTD.

EMPLOYMENT/RESEARCH

1/17 – present	University of South Florida Morsani College of Medicine Division Director of Gynecology Oncology Tampa, FL
1/17 – present	Tampa General Hospital Medical Director of Cancer Center Tampa, FL
7/15 – 1/17	University of Vermont College of Medicine Clinical Professor in the Volunteer Pathway Burlington, VT
1/15 – 1/17	Director of Gynecologic Oncology CT Gynecologic Oncology Avon, CT
1/15 – 1/17	Director of Western CT Health Network Cancer Center Director of Gynecologic Oncology Danbury, CT
6/11 – 1/15	Yale University School of Medicine New Haven, CT Professor – Gynecologic Oncology
11/11 – 6/14	Yale University School of Medicine New Haven, CT Interim Division Director of UroGynecology

10/05 – 6/14
Yale University School of Medicine
New Haven, CT
Division Director – Gynecologic Oncology

2/04 – 1/15
Yale University School of Medicine
New Haven, CT
Director of Gynecologic Oncology Fellowship

6/00 – 6/2011
Yale University School of Medicine
New Haven, CT
Associate Professor - Gynecologic Oncology

7/95 - 6/00
Yale University Medical School
New Haven, CT
Assistant Professor - Gynecologic Oncology

7/93 - 6/95
Yale University Medical School
New Haven, CT
Gynecologic Oncology Fellowship

12/90 - 6/93
Cooper Hospital/University Medical Center
Robert Wood Johnson Medical School
Camden, NJ
Residency in Obstetric and Gynecology

1/92 - 2/92
Memorial Sloan Kettering Hospital
New York, NY
Galloway Fellowship

6/89 - 11/90
Albert Einstein Medical Center
Philadelphia, PA
Residency in Obstetric and Gynecology

9/86 - 2/89
Medical College of Ohio at Toledo
Toledo, OH
Research Assistant, Pediatric Department

1/85 - 9/86
Medical College of Ohio at Toledo
Toledo, OH
Post-Doctoral Fellowship, Surgery Department

12/82 - 5/89
Toledo Hospital, Toledo, OH - Clinical Chemist

5/75 - 9/81
Rutherford Brothers Construction Co.
Hatfield, PA

LICENSURE

FL #ME130333
CT #032933
NJ #56890 (inactive)
PA #046132 L (inactive)
DEA #BR 3384409

BOARDS

Ob/Gyn Diplomat - 11/97
Gyn/Oncology- Board Certified - 4/00
Re-certification completed - 08/15

PUBLICATIONS

1. Appert HE, **Rutherford TJ**, Tarr GE, Thomford NR, McCorquodale DJ. (1986). Isolation of Galactosyltransferase from Human Milk and the Determination of its N-Terminal Amino Acid Sequence. *Biochem and Biophys Research Communication*, 138:224 - 229.
2. Appert HE, **Rutherford TJ**, Tarr GE, Weist JS, Thomford NR, McCorquodale DJ. (1986). Isolation of a cDNA Coding for Human Galactosyltransferase. *Biochem and Biophys Research Communication*, 139:163-168.
3. Duncan AM, McCorquodale MM, Morgan C, **Rutherford TJ**, Appert HE, McCorquodale DJ. (1986). Chromosomal Localization of the Gene for a Human Galactosyltransferase (GT-1). *Biochem and Biophys Research Communication*, 141: 1185 - 1188.
4. **Rutherford TJ**, Weist JS, McCorquodale DJ, (1986). A Protocol for Electro-eluting Oligomers Using the IBI Model UEA. *RE: Source*, 2:12.
5. Tayel S, McCorquodale MM, **Rutherford TJ**, Kurczynski TW, Abdel-Aziz AM, El-Gabaldy F, Shoraf EA. (1989). A Case of *de novo* Trisomy 12p Syndrome. *Clinical Genetics*, 35:382 - 386.
6. O'Brien MC, **Rutherford TJ**. (1993). Limitations of Transvaginal Sonography in the Emergency Department and Diagnosis of a Suspected Bilateral Ectopic Pregnancy. *J. of Em. Med.*, 6: 275-278.
7. Fernandez E, Goldberg J, Johnson E, **Rutherford TJ**, Barnea ER, Check JH, Grudzinskas JG, Maruo T. (1993). Cancer and pregnancy: Clinical management and biological analogy, Implantation and Early Pregnancy in Humans, Ed.
8. **Rutherford TJ**, Schwartz PE, Conn RB, Borer WZ, Synder JW. (1995). Benign and Malignant Ovarian Tumors, Current Diagnosis 9, Ed.
9. Naftolin F, **Rutherford TJ**, Chambers JT, Carcangiu ML. Wanted more evidence on whether estrogen replacement causes cancer. *J Soc Gynecol Investig*, 4 (2):57, Mar-Apr 1997.

10. Zreik TG, **Rutherford TJ**, Palter SF, Troiano RN, Williams E, Brown JM, Olive DL. Cryomyolysis: A new procedure for the conservative treatment for uterine fibroids. (1998) *J Am Assoc Gynecol Laparosc* 5(1):33-38.
11. **Rutherford TJ**, Zreik TG, Troiano RN, Palter SF, Olive DL. (1998) Endometrial Cryoblation, A minimally Invasive Procedure for Abnormal Uterine Bleeding. *J AM Assoc Gynecol Laparosc* 5;1:23-28.
12. Chambers JT, **Rutherford TJ**, Baker L, Kohorn EI, Schwartz PE, Carcangiu ML, Chambers SK. Serous carcinoma of the uterus treated with cisplatin, doxorubicin, and etoposide. (1998) *Int J Gynecol Cancer*, 8:193-196.
13. Roy WJ, **Rutherford TJ**, Schwartz PE. (1998) Current status of intraperitoneal chemotherapy in management of epithelial ovarian carcinoma and the role of lymphadenectomy. *CME J Gyn Oncol*. 3:107-116.
14. Horowitz K, **Rutherford TJ**, Schwartz PE. Hormone replacement therapy in women with sarcomas. (1998) *CME J Gyn Oncol*, 23-9.
15. Turner BC, Knisely JP, Kacinski BM, Haffty BG, Gumbs AA, Roberts KB, Frank AH, Peschel RE, **Rutherford TJ**, Edraki B, Kohorn EI, Chambers SK, Schwartz PE, Wilson LD. (1998) Effective Treatment of Stage I uterine Papillary Serous Carcinoma with High Dose-rate Vaginal Apex Radiation (¹⁹²Ir) and Chemotherapy. *Int J Rad Oncol Biol Phys* 40;1:77-84.
16. Schwartz PE, **Rutherford TJ**, Chambers JT, Kohorn EI, Thiel RP. (1999) Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: Long-Term Survival. *Gynecol Oncol*, 72:93-99.
17. Azodi M, Chambers SK, **Rutherford TJ**, Kohorn EI, Schwartz PE, Chambers JT. (1999) Adenocarcinoma in situ of the Cervix: *Management and Outcome*. *Gynecol Oncol*, 73:348-353.
18. Ohtani K, Sakamoto H, **Rutherford TJ**, Chen A, Satho K, Naftolin F. (1999) Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. *Cancer Letters*, 144:1-8.
19. **Rutherford TJ**, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. (2000) Absence of Estrogen Receptor-B Expression in Metastatic Ovarian Cancer. *Obstet Gyencol*, 96;3:417-421.
20. Zreik TG, **Rutherford TJ**. (2001) Psammoma bodies in cervicovaginal smears. *Obstet Gynecol*. 97;5:693-695.
21. Toy EP, **Rutherford TJ**. (2001) High-dose chemotherapy in the treatment of ovarian cancer. *CME J Gyn Oncol* 6;1:17-22.
22. Deisseroth A, Fujii T, Peng X, Zhang L, Austin D, **Rutherford T**, Bradma J, Schwartz P. (2001) Molecular chemotherapy. *CME J Gyn Oncol* 6;1: 23-28.

23. Peng XY, Won JH, **Rutherford TJ**, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal, R, Schwartz P, Deisseroth A. (2001) The use of the L-plastin promoter for Adenoviral mediated tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Research* 61;4405-4413.
24. Chen Z, Fadiel A, Feng Y, Ohtani K, Sakamoto H, **Rutherford T**, Naftolin F. (2001) Ovarian epithelial cell proliferation, ezrin translocation and tyrosine phosphorylation are stimulated by interleukin 1 α and epidermal growth factor. *Cancer* 92;12:3068-3075.
25. Song J, **Rutherford T**, Naftolin F, Brown S, Mor G. (2002) Hormonal regulation of apoptosis and the Fas/Fas ligand system in human endometrial cells. *Mol. Hum. Repro.* 8;5:447-455.
26. Sapi E, Brown W, Aschkenazi S, Munoz A, Kacinski B, **Rutherford T**, Mor G. (2002) Regulation of Fas ligand by estrogen in normal ovary *S. Gynecol Inv* 9;4:243-250.
27. Sapi E, Okpokwasili N, **Rutherford TJ**. (2002) Detection of Telomerase-positive circulating cells in ovarian cancer patients. *Cancer Det.and Prev.* 26:158-167.
28. Ohtani K, Sakamoto H, **Rutherford T**, Chen Z, Kikuchi A, Yamamoto T, Satoh K, Naftolin F. (2002) Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. *Cancer Let.* 179:79-86.
29. Aschkenazi S, Straszewski S, Verwer K, Foellmer H, **Rutherford T**, Mor G. (2002) Differential regulation and function of the Fas/Fas ligand system in human Trophoblast cells. *Biol. Repro.* 66:1853-1861.
30. Chambers JT, **Rutherford T**, Chambers SK, Schwartz P, Baker L. (2003) A pilot study of topotecan in the treatment of serous carcinoma of the uterus. *Int. J. Gyn. Ca.* 13:216-222.
31. Mor G, Sapi E, Abrahams VM, **Rutherford T**, Song J, Hao XY, Kohen F. (2003) Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. *J. Immuno.* 170:114-122.
32. Yalcin OT, **Rutherford TJ**, Chambers SK, Chambers JT, Schwartz PE. (2003) Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure. *Eur. J. Ob. Gyn.* 106:64-68.
33. Kamsteeg M, **Rutherford T**, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G. (2003) Phenoxodiol – an isoflavone analogue – induces apoptosis in chemo-resistant ovarian cancer cells. *Oncogen* 22:2611-2620.
34. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, **Rutherford TJ**, Mor, G. (2003) Epithelial ovarian cancer cells secrete functional Fas Ligand. *Cancer Res.* 63:5573-5581.

35. Flick MB, O'Malley DO, **Rutherford TJ**, Rodo S, Kamsteeg M, Hao XY, Schwartz P, Kacinski BM, Mor M. (2004) Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. *J. Soc. Gynecol. Investig.* 11;4:253-259 .
36. Zheng W, Liang SX, Yu H, **Rutherford TJ**, Chambers S, Schwartz P. (2004) Endometrial glandular dysplasia: A newly defined precursor lesion of uterine serous papillary serous carcinoma. Part 1: Morphologic features. *Int. J Surg Path.* 12(3):207-223.
37. Sapi E, Alvero A, Chen W, O'Malley D, Ying X, Dwipoyono B, Garg M, Kamsteeg M, **Rutherford TJ**, Mor G. (2004) Resistance of ovarian cancer cells to Docetaxel is XIAP dependent and reversible by Phenoxodiol. *Onco.Research* 14(11-12):567-578.
38. Kelly MG, O'Malley D, Hui J, Dziura J, **Rutherford TJ**, Azodi M, Chambers SK, Schwartz PE. (2004) Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. *Gyn Oncol.* 95:469-473.
39. Lane DB, **Rutherford TJ**, Taylor HS. (2004) HOX10 Expression in endometrial adenocarcinoma. *Tumor Biol.* 25:264-269.
40. Collins Y, Pejovic T, Mor G, Lele S, **Rutherford T**, McQuaid M, Nowak N, Odunsi K. (2004) Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinoma using cDNA microarray. *Int. j. Mol. Med.*, 14:43-53.
41. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, **Rutherford T**, Yue L, Brady-Ward P, Ward DC. (2005) Serum protein markers for early detection on ovarian cancer. *PNAS* 102(21):7677-7682.
42. O'Malley D, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, **Rutherford T**. (2005) Weekly Topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. *Gyn Onc* 98:242-248.
43. Kelly M, O'Malley D, Hui P, McAlpine J, Hu H, **Rutherford T**, Axodi M, Schwartz P. (2005) Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. *Gyn Onc* 98:353-359.
44. Alvero AB, Chen W, Sortotelli AC, Schwartz P, **Rutherford TJ**, Mor G. (2006) Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. *J Soc Gynecol Investig* 13;2:145-152.
45. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, **Rutherford T**, Mor G. (2006) Molecular mechanism of Phenoxodiol-induced apoptosis in ovarian cancer cells. *Cancer* 106;(3):599-608.
46. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, **Rutherford T**, Mor G. (2006) TLR-4 Signaling promotes tumor growth and Paclitaxel chemo-resistance in ovarian cancer. *Canc Res* 66;7: 3859-3868.

47. McAlpine JN, Kelly MG, O'Malley DM, Azodi M, Coombe K, Schwartz PE, **Rutherford TJ**. (2006) Atypical presentations of carboplatin hypersensitivity reactions: Characterization and management in patients with gynecologic malignancies. *Gyn Onc* 103;288-292.
48. Silasi D, Alvero A, Illuzi J, Kelly M, Chen R, Fu H, Schwartz P, **Rutherford T**, Azodi M, Mor G. (2007) MyD88 predicts chemo-resistance to paclitaxel in epithelial ovarian cancer. *Yale J of Biol and Med*. 79(3-4):154-163.
49. Agarwal R, Whang HW, Ayesha AB, Visintin I, Lai Y, Segal EA, Schwartz PE, Ward D, **Rutherford T**, Mor G. (2007) Macrophage migration inhibitory factor expression in ovarian cancer. *Am J of Ob Gyn* 196;e1-348.e5.
50. Beeghly AC, Katsaros D, Wiley AL, Rigault de la Longrais IA, Prescott AT, Chen H, Puopolo M, **Rutherford TJ**, Yu H. (2007) IGF-II promoter methylation and ovarian cancer prognosis. *J Cancer Research Clin Oncol*. 133(10):713-23.
51. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, **Rutherford TJ**, Schwartz PE. (2007) Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. *Gyn Oncol* 105;211-217.
52. Smith S, Su D, Rigault della Longrais IA, Schwartz P, Puopolo M, **Rutherford TJ**, Mor G, Yu H, Katsaros D. (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. *JCO* 25(33):5172-9.
53. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores R, Yu H, Azodi M, **Rutherford T**, Schwartz P, Mor G. (2008) Diagnostic markers for early detection of ovarian cancer. *Clin Canc Research* 14(4);1065-1072.
54. Silasi DA, Illuzzi JL, Kelly MG, **Rutherford T**, Mor G, Azodi M, Schwartz PE. (2008) Carcinosarcoma of the ovary. *Int J Gynecol Can* 18:22-29.
55. McAlpine JN, Hodgson EJ, Abramowitz S, Richman SM, Su Y, Kelly MG, Luther M, Baker L, Zelerman D, **Rutherford TJ**, Schwartz PE. (2008) The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies. *Gyn Onc* 109(2):296-302.
56. Chen R, Alvero AB, Silasi DA, Kelly M, Fest S, Visintin I, Leiser A, Schwartz P, **Rutherford T**, Mor G. (2008) Regulation of IKKbeta by miR-199a affects NF-kb activity in ovarian cancer cells. *Oncogene* 14:1-12.
57. Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, **Rutherford TJ**, Mor G. (2008) Anti-tumor activity of phenoxodiol from bench to clinic. *Future Oncol* 4(4):475-482.
58. Silasi DA, Schwartz PE, **Rutherford TJ**, Conn RB, Borer WZ, Synder JW. (2009). Benign and Malignant Ovarian Tumors, Current Diagnosis 9, Ed.

59. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2009) Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. *Am. J. Ob Gyn.* 200(1):75.e1-10.
60. Bellone S, Anfossi S, OBrien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2009) Generation of TADG-12-specific Cytotoxic T Lymphocytes in Human Leukocyte Antigen-A2.1 positive healthy Donors and Patients with Advanced Ovarian Cancer. *Cancer.* 115(4):800-11.
61. Alvero AB, Chem R, Fu HH, Montagna M, Schwartz PE, **Rutherford TJ**, Silasi DA, Steffensen KD, Waldstrom M, Visitin I, Mor G. (2009) Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. *Cell Cycle* 8:1, 158-166.
62. Su D, Smith SM, Preti M, Schwartz PE, **Rutherford TJ**, Menato G, Danese S, Ma S, Yu H. (2009) Strathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. *Cancer* 115;2453-2463.
63. Sadeghi H, **Rutherford T**, Duzyj C, Campbell C, Norwitz E. (2009) Cesarean scar ectopic pregnancy: Case series and review of the literature. *Am. J. Perinat.* 27(2)111-120.
64. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Siegel C, Buza N, Tavassoli F, Visintin I, Mor G, Azodi M, Schwartz P, **Rutherford T**, Pecorelli S, Santin A. (2009) Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. *Br. J. Cancer*
65. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2009) Overexpression of Epithelial Cell Adhesion Molecule (Ep-CAM) in Primary, Metastatic and Recurrent/Chemotherapy Resistant Epithelial Ovarian Cancer: implications for Ep-CAM-specific immunotherapy. *Int. J. Gynecol. Cancer.* 19(5):860-866.
66. Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmiere M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2009) HPV16 VLP L1-specific CD8+ cytotoxic T lymphocytes (CTL) are equally effective to E7-specific CD8+ CTL in killing autologous HPV16 positive tumor cells in cervical cancer patients: Implication for L1 dendritic cell-based therapeutic vaccines. *J Virol.* 83(13):6779-6789.
67. Silasi DA, Alvero AB, **Rutherford TJ**, Brown D, Mor G. (2009) Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. *Expert Opin Pharmacother* Apr;10(6):1059-67.
68. Richter CE, Qian B, Martel M, Yu H, Azodi M, **Rutherford TJ**, Schwartz PE. (2009) Ovarian preservation and staging in reproductive-age endometrial cancer patients. *Gynecol Oncol* 114(1):99-104.

69. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Bellone F, Buza N, Tavassoli FA, Schwartz PE, **Rutherford TJ**, Ravaggi A, Pecorelli S, Santin AD. (2009) Serum Amyloid A (SAA): a Novel Biomarker for uterine serous papillary cancer. *Br J Cancer* 101(2):335-341.
70. Ratner E, Toy E, O'Malley D, McAlpine J, **Rutherford TJ**, Azodi M, Higgins S, Schwartz PE. (2009) Brain metastases in epithelial ovarian and primary peritoneal carcinoma. *Int J Gynecol Cancer*. 19(5):856-9.
71. Xu M, Schwartz P, **Rutherford T**, Azodi M, Renshaw IL, Silasi D, Martel M, Hui P. (2010) HER-2/neu receptor gene status in endometrial carcinomas: A tissue microarray study. *Histopathology* 56(2):269-273.
72. El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2010) Over-expression of epithelial cell adhesion molecule (Ep-CAM) in uterine serous papillary carcinoma: implications for Ep-CAM-specific immunotherapy with MT201, a fully human monoclonal antibody. *Mol. Cancer Ther*, 9(1);57-66.
73. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2010) *In vitro* activity of Pertuzumab in combination with Trastuzumab in uterine serous papillary adenocarcinoma. *Br J. Cancer*. 102; 134-143.
74. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin L, Pelletier C, Blitzblau R, Paranjape T, Tassi R, Hu P, Godwin A, Yu H, Risch H, **Rutherford T**, Schwartz, P, Santin A, Matloff, E, Zelterman D, Slack F, Weidhaas J. (2010) A KRAS-variant as a Biomarker of Ovarian Cancer Risk. *Can. Res*. 70 (16):6509-6515.
75. Cross S, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, **Rutherford T**, Santin AD (2010) Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. *Am J Obstet Gynecol* 2010; 203:162-164.
76. Ratner ES, Tuck D, Richter C, Nallur S, Patel R, Schultz V, Hui P, Schwartz PE, **Rutherford TJ**, Weidhaas JB. Micro RNA signatures differentiate uterine cancer tumor subtypes. *Gynecol Oncol* 2010; 118:251-257
77. Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin A, Schwartz PE, **Rutherford T**. (2010) Her-2/Neu over-expression in vulvar Pagets' Disease – the Yale experience. *Gyn Onc. J Clin Pathol* 63;544-547.
78. Cocco E, Casagrande F, Bellone MS, Richter C, Bellone M, Todeschini P, Fu HH, Holmberg JC, Montagna MK, Mor G, Schwartz PE, **Rutherford T**, Pecorelli S, Santin AD. (2010) Clostridium perfringens enterotoxin carboxy-terminal fragment: A novel tumor-homing peptide for imaging and therapy of chemotherapy-resistant ovarian cancer. *BMC Cancer* 10:349-360.

79. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, **Rutherford T**, and Mor G. (2010) TWISTing Stemness, Inflammation, and Proliferation of Epithelial Ovarian Cancer Cells through MIR199A2/214. *Oncogene* 29;3545-3553.
80. Cocco E, Richter C, Bellone S, Casagrande F, Bellone M, Krukun P, Silasi D, Schwartz P, **Rutherford T**, Buzza N, Peccorelli S, Lockwood C, Santin A. (2010) H1-con1, a factor VII-IgFc chimeric protein targeting tissue for immunotherapy of uterine serous papillary carcinoma. *Br J Cancer* 103,812-819.
81. Leizer A, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, **Rutherford T**, Mor G. (2010) Regulation of inflammation by NF-kB pathway in ovarian cancer stem cells. *Am J Reprod Immunol*; 65(4):438-47. doi: 10.1111/j.1600-0897.2010.00914.x. Epub
82. Richter CE, Cocco E, Bellone S, Silasi DA, Ruttinger D, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2010) High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. *Int J Gynecol Cancer* 2010; 20:1440-7.
83. Kelly MG, Mor G, Husband A, O'Malley D, Baker L, Azodi M, Schwartz PE, **Rutherford TJ**. (2011) Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane refractory/resistant epithelial ovarian, fallopian tube or primary peritoneal cancers. *Int. J. Gyn Can.* 21(4):633-639.
84. Varughese J, Cocco E, Bellone S, Schwartz PE, **Rutherford T**, DeLeon M, Pecorelli S, Lockwood C, Santin A. (2011) Uterine Serous Papillary Carcinomas over-express human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. *Gynecol Oncol* 2011; 122:171-177.
85. Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, **Rutherford TJ**, Santin AD. Trop-2 overexpression in poorly differentiated endometrial endometrioid adenocarcinoma: Implications for immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. *International Journal of Gynecologic Cancer*, 2011 Dec;21(9):1613-21.
86. Roberts KE, Solomon D, Mirensky T, Silasi D, Duffy AJ, **Rutherford T**, Longo WE, Bell RL. (2011) Pure transvaginal appendectomy versus traditional laparoscopic appendectomy for acute appendicitis: A prospective cohort study. *Ann Surg.* 255(2): 266-9. doi: 10.1097/SLA.0b013e31823b2748.
87. Steffensen K, Alvero A, Yang Y, Waldstrom M, Hui P, Holmberg J, Silasi DA, Jakobsen A, **Rutherford TJ**, Mor G. (2011) Prevalence of epithelial ovarian cancer stem cells correlates with early recurrence in early stage ovarian cancer. *J. Oncol.* 620523. doi: 10.1155/2011/620523.

88. Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz P, **Rutherford T**, Pecorelli S, Santin A. (2011) High-grade chemotherapy-resistant primary ovarian carcinoma cell lines over-express human trophoblast cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. *Gyn Onco*. 122:171-177.
89. Bellone M, Bellone S, Varughese J, Cocco E, Todeschini P, ElSahwi KS, Carrara L, Guzzo F, Schwartz P, **Rutherford T**, Pecorelli S, Marshall D, Santin A. (2011) Expression of alphaV- integrins in uterine serous papillary carcinomas: Implications for targeted therapy with intetumumab (CNT095), a fully human antagonist anti-alphaV-intergrin antibody. *Int. J. of Gynecol. Cancer*. 21:1084-1090.
90. Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Carrara L, Guzzo F, Siegel F, Varughese J, Silasi DA, Azodi M, **Rutherford T**, Pecorelli SL, Schwartz PE, Santin A. (2011) Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of *clostridium perfringens* enterotoxin. *Cancer*. 21:1084-1090.
91. Lu L, Schwartz PE, Scarampi L, **Rutherford TJ**, Canuto EM, Katsaros D, Yu H. (2011) MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. *Gyn Onc* 122:366-371.
92. Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, **Rutherford T**, Hu H. (2011) Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. *Inter. J. Cancer* 129(5): 1237-1243.
93. Cross SN, Ratner ES, Silasi DA, Santin AD, Azodi M, **Rutherford TJ**, Schwartz PE. (2011) Bevacizumab related hypertension and reversible posterior leuko-encephalopathy syndrome in gynecologic malignancies: A case control study. *J Can. Thera*. 2(2): 217-223.
94. Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AS. (2011) Tissue factor expression in ovarian cancer: implications for immunotherapy with HI-con 1, a factor VII-IgGFc chimeric protein targeting tissue factor. *Clin Exp. Metastasis*. 28 (7): 689-700.
95. Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, **Rutherford T**, Pecorelli SL, Lockwood CJ, Santin A. (2011) Expression of Tissue factor in Adenocarcinoma and Squamous cell carcinoma of the cervix: Implications for immunotherapy with hI-con 1, a factor VII-IgGFc chimeric protein targeting tissue factor. *BMC Cancer* 11:263
96. Todeschini P, Cocco E, Bellone S, Varguhese J, Gzzo F, Buza N, Hui P, Silasi D-A, Ratner E, Azodi M, Schwartz P, **Rutherford T**, Pecorelli S, Santin A. (2011) Her2/neu extracellular domain shedding in uterine serous carcinoma; implications for immunotherapy with trastuzmab. *B. J. Cancer* 105:1176-1182.

97. Richter C, Cocco E, Bellone S, Bellone C, Casagrande F, Todeschini P, Ruttinger D, Silasi D, Azodi M, Schwartz PE, **Rutherford T**, Pecorelli S, Santin AD. (2011) Primary cervical carcinoma cell lines over-express epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. *Int J Gynecol Cancer* 20(9):1440-7.
98. ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D-A, Santin A, Azodi M, Schwartz P, **Rutherford TJ**. (2011) The significance of perineural invasion in early-stage cervical cancer. *Gyn Onc* 123:561-564.
99. ElSahwi KS, Hooper C, DeLeon MC, Gallo TN, Ratner E, Silasi DA, Schwartz PE, **Rutherford TJ**, Azodi M. (2011) Comparison of 155 cases of Robotic vs. 150 cases of open surgical staging for endometrial cancer. *Gyn Oncol*. 124(2):260-264.
100. Raji R, Guzzo F, Carrar L, Varughese J, Cocco E, Bellone S, Bette M, Todeschini P, Gasparini S, Ratner E, Silasi DA, Azodi M, Schwartz P, **Rutherford T**, Buza N, Pecorelli S, Santin A. (2011) Uterine and ovarian carcinosarcomans over-expressing Trop-2 are sensitive to hR57, a humanized anti-Trop-2 antibody. *J Exp Clin Canc Research*. 30:106.
101. Varughese J, Cocco E, Bellone S, Buza N, Ratner E, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2011) Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. *American Journal of Obstetrics and Gynecology*, 205(6):567.e1-7.
102. Ratner E, Keene F, Yu H, Zeltermann D, **Rutherford T**, Santin A, Schwartz P, Weidhaas J. (2011) Retraction to "A 3 UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer" *Gynecol Oncol* 120
103. Nelson WK, Formica RN, Cooper DL, Schwartz PE, **Rutherford TJ**. (2012) An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. *J Onc Phar Pract*. 18:323-332.
104. Carrara L, Guzzo F, Roque DM, Gasparrine S, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, **Rutherford TJ**, Santin AD. (2012) Differential *in vitro* sensitivity to paclitaxel versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. *Gynecol Oncol*. 125:231-236.
105. Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, **Rutherford TJ**, Angioli R, Pecorelli S, Santin, A. (2012). HER2/neu as a potential target for immunotherapy in gynecological carcinosarcomas. *International Journal of Gynecological Pathology*. 31(3):211-221.
106. ElSahwi K, Illuzzi J, Varughese J, Carusillo N, Ratner E, Silasi DA, Azodi M, **Rutherford TJ**, Schwartz PE, Santin AD. (2012) A Survey of Gynecologic Oncologists Regarding the End-of-Life Discussion: A Pilot Study. *Gynecologic Oncology*. 124(3):471-3.

107. Bellone S, Roque D, Cocco E, Gasparrin S, Bortolomai I, Buza N, Abu-khala M, Silasi DA, Ratner E, Azodi M, Schwartz PE, **Rutherford TJ**, Pecorelli S, Santin AD. (2012) Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. *BJC* 106:1543-1550.
108. Roque DM, Bellone S, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, **Rutherford T.J**, Schwartz PE, Santin AD. (2012) Tubulin β -III over-Expression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to Etoposides. *Cancer* 119:2582-92.
109. DeLeon M, Santin A, **Rutherford TJ**, Silasi DA, Azodi M, Ratner E, Schwartz PE. (2012) Uterine serous carcinoma: Prognostic factors and treatment – related outcomes. *Gyn Onc.* 30, (suppl; abstr 5099)
110. Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, **Rutherford TJ**, Schwartz PE, Pecorelli S, Santin AD. (2013) Class III β -tubulin overexpression after platinum/taxane chemotherapy and sensitivity to paclitaxel. *Am J Obstet Gynecol.* 209:62-64.
111. Liu M, Mor G, Cheng H, Xiang X, Hui P, **Rutherford T**, Yin G, Rimm D, Holmberg J, Alvero A, Silasi D. (2012) High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. *Reprod Sciences* 20(5); 605-615
112. Ishiguro K, Shyam K, Penketh PG, Baumann RP, Ratner ES, **Rutherford TJ**, Sartorelli AC. (2013) Expression of O6-methylguanine-DNA methyltransferase examined by alkyl-transfer assays, methylation-specific PCR and western blots in tumors and matched normal tissue. *J Cancer Ther.* 4; 919-931.
113. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, **Rutherford T**, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. (2013) Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. *Proc Natl Acad Sci USA* 110(8):2916-2921.
114. English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, **Rutherford T**, Santin AD. (2013) Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC 1/2). *Am J Obstet Gynecol.* 20(5):465.

115. Zhao S, Choi M, Bellone S, Roque D, Cocco E, Guzz,F, English D, Varughese J, Gasparini S, Bartolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi D, Ratner E, Azodi M, Schwartz P, **Rutherford T**, Stiegler A, Boggon T, Schlessinger J, Lifton R, Santin A. (2013) Uterine serous carcinoma sequencing reveals mutations of TAF1 and CHD4 and common amplifications of the ERBB2, PIK3CA and CCNE1 genes. PNAS 110:2916-21.
116. Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, **Rutherford TJ**, Schwartz PE, Pecorelli S, Santin AD. (2013) Class III B-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to paclitaxel. Am J Obstet Gynecol. 209: 62.e1-9.
117. Glasgow MA, Yu H, **Rutherford TJ**, Azodi M, Silasi DA, Santin AD, Schwartz PE. (2013) Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol. Feb;107(2):195-200.
118. Craveiro V, Yang-Hartwich Y, Holmberg J, Joo WD, Sumi N, Pizzoni J, Griffin B, Gill S, Silasi D, Azodi M, **Rutherford T**, Alvero A, Mor G. (2013) Phenotypic modifications in ovarian stem cells following Paclitaxel treatment. Can Med. 2:751-762.
119. Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparini S, Bortolomai I, Black J, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighiere L, Falchetti M, Donzelli C, Siegel E, Azodi M, Silasi D, Ratner E, Schwartz PE, **Rutherford T**, Santin A. (2013) Mammaglobin B (SCGB2A1) is a novel tumor antigen highly differentially expressed in all major histologic types of ovarian cancer; Implications for ovarian cancer immunotherapy. BJC 109:462-471.
120. Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, **Rutherford TJ**, Schwartz PE, Santin AD. (2013) Tubulin-b-III overexpression by uterine serous carcinomas is a poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 119(14)2582-2592.
121. **Rutherford T**, Orr J, Grendys E, Edwards R, Krivak T, Holloway R, Moore R, Puls L, Tilmanns T, Schink J, Brower S, Tian C, Herzog T. (2013) A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gyn Onc 131:362-367.
122. Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, **Rutherford T**, Schwartz PE, Abu-Khalaf MM. (2014) Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Int. J Gynecol Cancer Mar;24(3):528-33.
123. English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, **Rutherford T**, Santin AD. (2014) T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med Jun 2.

124. Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, **Rutherford TJ**, Santin AD, Silasi DA. (2014) Impact of body mass index on surgical outcomes and analysis of disease recurrence for patients with endometrial cancer undergoing robotic assisted staging. *Int. J Gynecol Cancer* Jul;24(6):1118-25.
125. Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparini S, Cocco E, Ratner E, Silasi DA, Azodi M, **Rutherford TJ**, Schwartz PE, Santin AD. (2014) Class III - β tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. *Clin Exp Metastasis*. 31(1):101-10.
126. Carlos A, Santin A, Higgins S, Shweta U, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Abu-Khalaf M. (2014) Phase I clinical trial of mammalian target Rapamycin inhibitor Everolimus in combination with oral Topotecan for recurrent and advanced endometrial cancer, *Int J GynOnc*. 24(3):528-533.
127. English D, Roque D, Carra L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz P, **Rutherford T**, Santin A. (2014) HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTOR1/2 inhibitor. *Gyn Onc* 131;753-758.
128. Plamadeala V, Kelley J, Chan J, Krivak T, Gabrin M, Brower S, Powell M, **Rutherford T**, Coleman R. (2015) A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. *Gyn Onc*. 136(1):94-98.
129. Schwab C, Bellone S, English D, Roque D, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D, Azodi M, Schwartz P, **Rutherford T**, Santin A. (2014) Afatinib demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. *BJC*. 111, 1750-1756.
130. English D, Bellone S, Schwab C, Roque D, Lopez S, Bonazzoli I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz P, **Rutherford T**, Santin A. (2014) Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. *Cancer*. 121(3):403-412.
131. Schwab C, Lopez S, Cocco E, Bellone S, Bonazzoli E, English D, Schwartz P, **Rutherford T**, Angioli R, Santin A. (2014) Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. *Gyn Onc*. 135(2):312-317.
132. Ishiguro K, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Zhu Y, Sartorelli AC, **Rutherford TJ**, Ratner ES. (2014) Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes. *Biochem Pharma* 91:312-322.

133. Brower S, Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Powell MA, **Rutherford TJ**, Coleman RL. (2015) A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. *Gyn Onc.* 136(1):94-98.
134. Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi D, Azodi M, **Rutherford T**, Schwartz PE, Damast S. (2014) Adjuvant carboplatin, paclitaxel and vaginal cuff Brachytherapy for stage III endometrial cancer: Analysis of outcomes and patterns of recurrence based on pathologic characteristics. *Int. J. Gyn Can.* 25(3):431-439.
135. Lopez S, Cocco E, Bellone S, Bonazzoli E, Nicoletti R, Centritto F, Black J, Schwab C, English D, Bussi B, Terranova C, Schwartz P, **Rutherford T**, Angioli R, Santin A. (2015) Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations. *Gyn Oncol.* 137:144.
136. Seagle B, Dawson M, Samuelson R, Chacho M, **Rutherford T**, Shahabi S. (2014) Feasibility, Sensitivity, and Specificity of post procedure peritoneal cytology. *Repro Sci.* 22(7):808-813.
137. Erekson E, Fried T, Martin D, **Rutherford T**, Strohhahn K, Bynum J. (2015) Frailty, cognitive impairment, and functional disability in older women seeking treatment for pelvic floor disorders. *Int Urogyn J.* 26(6):823-830.
138. Damast S, Higgins SA, Ratner E, DeLeon MC, Mani S, Silasi D, Azodi M, Santin A, **Rutherford T**, Schwartz PE. (2015) High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. *J Contemp Brachy.* 7(1):35-40.
139. Wang Z, Risch H, Lu L, Irwin M, Mayne S, Schwartz P, **Rutherford T**, De Vivo I Yu H. (2015) Joint effect of Genotype and Phenotype features of reproductive factors on endometrial cancer risk. *Sci Reports.* 5:15582. DOI: 10.1038/srep15582
140. Schwab C, English D, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Santin A. (2015) Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. *Gyn Onc.* 139(1):112-117.
141. Black J, Roque D, Pasternak M, Buza N, **Rutherford T**, Schwartz P, McCarthy S, Ratner E. (2015) A Series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. *Int J Gynecol Cancer.* 25(5):792-797.
142. Coleman R, Sill MW, Bell-McGuinn K, Aghajanian CA, Gray HJ, Tewari KS, Rubin SC, **Rutherford TJ**, Chan JK, Chen A, Swisher EW. (2015) A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study *Gyn Onc.* 137(3):386-391.

143. Roque D, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Nelson W, Santin S. (2015) Weekly ixabepilone with biweekly bevacizumab in the treatment of advanced, recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers. *Gyn Onc.* 137(3):392-400.
144. Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, **Rutherford TJ**. (2015) Management of borderline ovarian tumors based on patient and tumor characteristics. *Gyn Obst Invest.* 81(2):169-173.
145. Schwab CL, Roque DM, English DP, Bellone S, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi A, Schwartz PE, **Rutherford TJ**, Santin AD. (2015) Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. *Gyn Onc.* 136(2):397-398.
146. Pasternak M, Jorgensen E, Azodi M, Ratner ES, **Rutherford TJ**, Santin A, Schwartz PE, Siliasi DA. (2015) Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome. *Gyn Oncol.* DOI: 10.1016/j.ygyno.2015.01.184.
147. Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, **Rutherford TJ**, Santin A, Schwartz PE. (2015). Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. *Gyn Oncol.* Oct 139(1):112-7.
148. Black JD, Lopez S, Bellone S, Schwab CL, English DP, Roque DM, Silasi DA, Ratner ES, Azodi M, **Rutherford TJ**, Schwartz PE, Santin A. (2015) Mutations in the PIK3 pathway as a major determinant of Trastuzumab resistance in uterine serous carcinoma. *Gyn Onc.* 137-161-162.
149. Cocco E, Shapiro EM., Gasparini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, **Rutherford TJ**, Schwartz PE, Pecorelli S, Santin A.D. (2015) Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micro-metastatic chemotherapy-resistant ovarian cancer: Real-time imaging of ovarian cancer using fluorescent c-CPE. *Int J Can.* 137(112): DOI:10.1002/ijc.29632
150. Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, **Rutherford TJ**, Ratner ES. (2016) Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian cancer cell lines. *J.Transla. Sci.* 2(2):117-124.
151. Von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, **Rutherford TJ**, Higgins RV, Secord AA, Fleming G. (2016) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer-An NRG oncology/Gynecologic Oncology Group Study *Gyn Onc.* (submitted)

152. Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, **Rutherford TJ**, Brewster WR, O'Malley DM, Partridge EE, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek SM, Davidson SA, Edwards RP, Elg SA, Wakeley K, Phillips KA, Armstrong DK, Horowitz IR, Fabian CJ, Walker J, Sluss PM, Welch WR, Minasian L, Horick N, Kasten CH, Nayfield S, Alberts DS, Finkelstein DM, Lu K. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. *Clin Cancer Res.* 2017 Jan 31.
153. Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, **Rutherford TJ**, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L. (2017) Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol.* 2017 Feb 10.
154. Uma Deshmukh, U, Black, J, Perez-Irizarry, J, Passarelli, R, Levy, k, Rostkowski, A, Hui, P, **Rutherford, T J**, Santin, A D, Azodi, M, Silasi, D A, Ratner, E, Litkouhi, B, Schwartz, P E. (2018) Adjuvant hormonal therapy for low-grade stromal sarcoma. *Repro Sci* Vol 26, 5:600-608.
155. Randall, M.E., Filiaci, V, McMeekin, S, von Gruenigen, V, Huang, H, Yashar, C.M., Mannel, R,S, Kim, J,W, Salani, R, DiSilvestro, P,A, Burke, J, J, **Rutherford, T**, Spirtos, N,M, Terada, K, Anderson, P, R, Brewster, W,R, Small, W, Aghajanian, C,A, Miller,D,S. (2019) Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus Paclitaxel/Carboplatin in high-intermediate and high-risk early stage endometrial cancer. *JCO* <https://ascopubs.org/doi/abs/10.1200/JCO.18.01575>.
156. Mor, G, **Rutherford, T**, Alvero, A - Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early State Ovarian Cancer” *Cancers* 2019, 11, 596, Markers for Early Detection of Ovarian Cancer <https://doi.org/10.3390/cancers11091307> 2019 Sept 5.
157. Mai, P.L., Huang, H.Q., Wenzel, L.B., Han, P.K., Moser, R.P., Rodriguez, G.C., Boggess, J., **Rutherford, T.J.**, Cohn, D.E., Kauff, N.D., Phillip, K.A., Wilkinson, K., Wenham, R.M., Hamilton, C., Powell, M.A., Walker, J.L., Greene, M.H., Hensley, M.L. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study 2019 Nov 2.
158. Randall, M.E., Filiaci, V., McMeekin, D.S., von Gruenigen, V., Huang, H., Yashar, C.M., Mannel, R.S., Kim, J.W., Salani, R., DiSilvestro, P.A., Burke, J.J., **Rutherford, T.**, Spirtos, N.M., Terada, K., Anderson, P.R., Brewster, W.R., Small, W., Aghajanian, C.A., and Miller, D.S. - Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. *Journal of Clinical Oncology* 2019 Apr 17.

CASE REPORTS

1. **Rutherford TJ**, Schwartz PE. (1996) Case Report: Familial Breast/Ovarian Cancer. Expert Consultations in Gynecological Cancers, Case 3, p.26.
2. **Rutherford TJ**, Chambers SK. (1996) Case Report: Stage I Endodermal Sinus Tumor. Expert Consultations in Gynecological Cancers, Case 16, p. 13.
3. **Rutherford TJ**, Chambers SK, Schwartz PE. (1996) Case Report: Elevated CA-125 Postmenopausal Patient. Expert Consultations in Gynecological Cancers, Case 22, p. 175.
4. **Rutherford TJ**, Chambers JT. (1996) Case Report: Recurrent Ovarian Cancer 4 Years After Initial Diagnosis. Expert Consultations in Gynecological Cancers, Case 33, p. 255.
5. **Rutherford TJ**, Fishman DA, Schwartz PE. Mid-gut volvulus in gynecologic oncology. J Gynecol Techniques, March 1998; 4:37-40.
6. Zreik TG, Pustilnik TB, Garcia-Velasco JA, **Rutherford TJ**, Troiano RN, and Olive DL. (1998) Unicornuate uterus with Rudimentary Horn and Ovarian Dysgerminoma. J. Reprod Med.
7. Odunsi KO, Olive DL, **Rutherford TJ**, Zreik TG. (1988) Abscess Formation in a Uterine Fibroid Treated with Cryomyolysis: A Case Report. J. Gynecol Tech Vol. 4, No.3 p. 115-118.
8. Pal L, Parkash V, **Rutherford TJ**. (2003) Omental trophoblastic implants and hemoperitoneum after laparoscopic salpingostomy for ectopic pregnancy. A case report. J. Reprod Med. 48(1):57-59.
9. McAlpine J, Azodi M, O'Malley D, Kelly M, Golenewsky G, Martel M, **Rutherford T**, Tavassoli F. (2005) Extra-renal Wilm's tumor of the uterine corpus. Gyn Oncol 96:892-896.
10. Bernstein EM, Tate A, Silasi DA, **Rutherford T**. (2009) Benign multicystic mesothelioma: a case report of three sisters. Rare tumors, 1:e46;69-71.
11. Cross SN, Ratner E, **Rutherford TJ**, Schwartz PE, Norwitz ER. (2012) Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Obstet Gynecol 201;5 xxx-xxx.

ABSTRACT

1. Appert HE, **Rutherford TJ**, Tarr GE, McCorquodale MM, Weist JS, Thomford NR, McCorquodale J. (1986) Isolation of cDNA for Human Galactosyltransferase. Annual Meeting for the American Society of Human Genetics.
2. Kopita J, **Rutherford TJ**, Tayel A, Cummin T, Kurczynski TW, McCorquodale MM. (1987) Lack of Correlation Between d(NORs)and Down Syndrome. *The American Journal of Human Genetics*,41:373

3. Peng XY, Crystal R, **Rutherford TJ**, Pizzorno G, Schwartz P, Chung I, Leavitt J, Deisseroth A. (1988) Adenov. Rai Vector Mediated Chemotherapy Sensitization which is Tumor Specific and Kills Non-Dividing Cells. AACR Annual Meeting.
4. McCorquodale MM, **Rutherford TJ**. (1989) Failure to Obtain Cytogenetic Results from Acidotic Blood Samples. Annual Meeting for the American Society of Human Genetics.
5. **Rutherford TJ**, Kurczynski TW, Brookfield EG, Brown KJ, McCorquodale MM. (1989) First Detailed Clinical Description of a 2q Deletion in Region 2q 1: Further Evidence of a 2q Deletion Syndrome. Annual Meeting for the American Society of Human Genetics.
6. **Rutherford TJ**, Schwartz PE, Chambers JT, Kohorn EI, Chambers SK. (1994) Thromboembolic Episodes and Nulliparity are Poor Prognostic Factors for Survival in Patients with Clear Cell Carcinoma of the Ovary. Annual meeting for the Northeastern Association of Gynecologic Oncologist.
7. **Rutherford TJ**, Chambers JT, Chambers SK. (1995) Expression of HER-2/neu, t-PA, and PAI-1 in Ovarian (OV) and Endometrial (Endo) Early Stage Clear Cell Carcinoma (CCC). Annual Meeting for the Northeastern Association of Gynecologic Oncologist.
8. Turner B, Knisely J, Kacinski B, Roberts K, Peschel R, Gumbs A, **Rutherford TJ**, Edraki B, Schwartz PE, Chambers SK, Chambers JT, Kohorn EI, Wilson L. (1995) Post-Operative high dose rate vaginal apex brachytherapy in stage I endometrial adenocarcinoma.
9. Rosser JC, Olive DL, Zreik T, Duleba A, Arici A, **Rutherford TJ**, Palter SF. (1996) Decreased performance of skilled laparoscopic surgeons at micro-laparoscopy versus traditional laparoscopy. International Congress of Gynecologic Endoscopy. International Congress of Gynecologic Endoscopy.
10. **Rutherford T**. (1996) Cryosurgery: A Simple Modality for Endometrial Ablation. International Congress of Gynecological Endoscopy.
11. Olive DL, **Rutherford TJ**, Zreik T, Palter S. (1996) Cryomyolysis: A New Approach to the Conservative Treatment of Uterine fibroids. International Congress of Gynecologic Endoscopy.
12. **Rutherford TJ**. (1998) High dose chemotherapy utilizing tandem stem cell transplant for initial treatment of high risk ovarian cancer. Annual Meeting of the American Society of Clinical Oncology.
13. Brown W, Mor G, **Rutherford T**, Tartaro K, Sapi E. (2000) Blue Ribbon Presentation: Fas ligand expression is regulated in normal and neoplastic tissue. SGI, Chicago IL, Abstract #41.
14. **Rutherford T**, Sapi E, Brown W, Verwer K, Munoz A, Mor G. (2000) Blue Ribbon Presentation: Fas and Fas ligand expression in normal and pathologic ovarian tissue. SGI, Chicago IL, Abstract #9.

15. Song J, Aschkenazi S, **Rutherford T**, Naftolin F, Mor G. (2001) Differential activation of the Fas ligand promoter by SERMs is dependent on the estrogen receptors ER α and ER β subtypes. SGI, Toronto
16. Song J, Naftolin F, Aschkenazi S, **Rutherford T**, Mor G. (2001) Effect of estrogen on Fas Ligand promoter activity. SGI, Toronto, Abstract #816.
17. Aschkenazi S, **Rutherford T**, Song J, Lim C, Mor G. (2001) Thalidomide induces Fas-mediated apoptosis in epithelial ovarian cancer. SGI, Toronto, Abstract #72.
18. Aschkenazi S, **Rutherford T**, Sapi E, Song J, Mor G. (2001) Cytotoxicity to Taxol in epithelial ovarian cancer cells is mediated by the Fas/Fas ligand system; *in vitro* assessment of drug sensitivity. SGI, Toronto, Abstract #277.
19. Lane D, **Rutherford T**, Taylor H. (2002) Altered HOX gene expression in high grade endometrial adenocarcinoma. SGI, CA.
20. Kohorn EI, Chambers SK, **Rutherford T**, Schwartz PE. (2002) The experience of the Yale Center for Trophoblastic Disease, 1971 to 2001. NEAGO
21. O'Malley D, Flick MA, Rodov S, Kacinski B, **Rutherford T**, Schwartz PE, Mor G. (2003) Correlation of *in vitro* apoptosis and clinical response to chemotherapy in ovarian cancer patients. SGI.
22. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, **Rutherford T**, Mor G. (2003) Ovarian cancer cells release a secretory form of Fas Ligand. SGI.
23. Mor G, Ying Xian, Dwipoyono B, Sapi E, Kamsteeg M, **Rutherford T**. (2003) Resistance of ovarian cancer cells to Taxotere is XIAP dependent. SGI.
24. Mor G, Kamsteeg M, Sapi E, Shahabi S, **Rutherford TJ**. (2003) Phenoxodiol-an isoflavone analogue-induces apoptosis in chemo-resistant ovarian cancer cells. SGI.
25. O'Malley DM, Kelly MG, McAlpine J, Morosky C, Dziura J, Azodi M, Schwartz PE, Higgins, SA, **Rutherford TJ**. (2005) An updated comparison of adjuvant chemotherapy to radiation in advanced type-1 endometrial cancer (EAC). NEAGO
26. Kelly MG, O'Malley DM, Hui P, McAlpine J, **Rutherford TJ**, Azodi M, Schwartz PE. (2005) Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with platinum-based chemotherapy. NEAGO
27. McAlpine J, O'Malley DM, Kelly MG, Coombe K, **Rutherford TJ**, Azodi M, Schwartz PE. (2005) Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies. NEAGO
28. Kelly M, Mor G, O'Malley D, Baker L, McAlpine J, Azodi M, Schwartz P, **Rutherford T**. (2006) Phase II evaluation of Phenoxodiol in combination with Cisplatin or Paclitaxel in Platinum/Taxane-refractory ovarian cancer. SGO.

29. Santin A, Bignotti E, Belione S, Ravaggi A, Tassi R, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicin F, Azodi M, Schwartz P, Pecorelli S, **Rutherford T**. (2008) Trefoil factor (TFF3): A novel serum marker identified by gene expression profiling in poorly differentiated endometrial carcinomas. NEAGO
30. Santin A, Anfosse S, O'Brien T, Cannon M, Pecorelli S, Azodi M, Arin-Silasi D, Schwartz P, **Rutherford T**, Bellone S. (2008) Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1 positive healthy donors and patients with advanced ovarian cancer. Int. Gynecol. Cancer Soc.
31. Santin A, Bignotti E, Belone S, Ravaggi A, Tassi R, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odincino F, Azodi M, Schwartz P, **Rutherford T**, Pecorelli S. (2008) Trefoil Factor 3 (TFF3): A novel serum marker identified by gene expression profiling in poorly differentiated endometrial carcinomas. Int. Gynecol. Cancer Soc.
32. Silasi DA, Alvero AB, Chen R, Fu HH, Montagna M, Visintin I, Schwartz M, Azodi M, **Rutherford T**, Mor G. (2008) Identification and characterization of cancer stem cells in ovarian cancer. 13th World Congress on Advances in Oncology.
33. Chen R, Silasi DA, Alvero AB, **Rutherford T**, Mor G. (2008) miR-199a regulates IKKbeta expression and function in ovarian cancer stem cells. 13th World Congress on Advances in Oncology.
34. Ratner E, Richter C, Nallur S, **Rutherford T**, Schwartz P, Azodi M, Weidhaas J. (2008) A novel microRNA expression profile associated with endometrial cancer. AACR.
35. Ratner E, Boeke M, Lingeng L, Barnett R, Yu H, Risch H, **Rutherford T**, Schwartz P, Matloff E, Zeltmer D, Slack F, Weidhaas J. (2009) A Kras3'UTR SNP as a new marker of ovarian cancer risk. SGO 40th meeting.
36. Santin A, Bellone S, El-Sahwi K, Buza N, Tavassoli A, Silasi D, Azodi M, Schwartz P, **Rutherford T**, Pecorelli S, Santin, A. (2009) Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. ASCO.
37. Ratner, ES, Richter, C, Patel, RM, Boeke, M, Zelterman, D, Santin, A, Azodi, M, Schwartz, PE, **Rutherford, TJ**, Hui, P, Weidhaas, J (2009) MicroRNA signature differentiates organ origin of serous gynecologic cancers. SGO 40th Meeting.
38. El-Sahwi K, Cocco E, Bellone S, Cargnelutti M, Siegel C, Buza N, Tavassoli F, Visintin I, Mor G, Azodi M, Schwartz P, **Rutherford T**, Pecorelli S, Santin A. (2009) Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. SGO 40th meeting.
39. Wang H, Lin KY, Merl MY, Higgins SA, Silasi DA, Santin A, Azodi M, **Rutherford T**, Schwartz PE, Abu-Khalaf MM. (2010) Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma. ASCO (June 4-8, 2010).

40. Schwartz PE, Glasgow MG, Yu H, **Rutherford T**, Azodi M, Silasi DA, Santin A. (2010) Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advanced stage (AS) epithelial ovarian cancer (EOC) compared to upfront surgical cytoreduction (USC) followed by CP. ASCO (June 4-8, 2010).
41. Katz A, Yu K, Elshawi K, Ratner E, Silasi DA, Santin A, Azodi M, **Rutherford T**, Schwartz PE, Abu-Khalaf MM. (2010) Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age ≥ 70 . ASCO (June 4-8, 2010).
42. Richter CE, Cocco E, Bellone S, Casagrande F, Bellone M, Silasi DA, Azodi M, Schwartz PE, **Rutherford T**, Santin A. (2010) EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201) in chemotherapy-resistant ovarian cancer cell lines. ASCO (June 4-8, 2010).
43. Cocco E, Varughese J, Richter C, Casagrande F, Elshawi K, Bellone S, Todeschini P, Pecorelli S, **Rutherford T**, Schwartz P, Silasi DA, Santin A. (2010) Uterine Serous carcinomas over-express human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. AACR (2010)
44. Richter CE, Cocco E, Bellone S, Casagrande F, Bellone M, Silasi DA, Azodi M, Schwartz PE, **Rutherford T**, Santin A. (2010) Chemotherapy-resistant ovarian cancer cell lines over-express EpCAM and are highly sensitive to EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). NEAGO (6/2010).
45. DeLeon M, El-Sahwi K, **Rutherford T**, Silasi D, Schwartz P, Santin A, Azodi M. (2010) One hundred fifty cases of Robotic-assisted staging for endometrial cancer: Experience of a single surgeon at an academic institution. NEAGO 6/2010.
46. Hooper C, El-Sahwi, K, **Rutherford T**, Silasi D, Schwartz P, Santin A, Azodi M. (2010) To compare 150 cases of endometrial cancer who had robotic-assisted surgical staging to 150 open cases. NEAGO 6/2010.
47. El-Sahwi K, Barber E, Illuzzi J, Silasi D, Schwartz P, Santin A, Azodi M, **Rutherford T**. (2010) The significance of perineural invasion in early stage cancer of the cervix. NEAGO 6/2010.
48. Wang H, Lin K, Merl MY, Higgins SA, Silasi DA, Santin A, Azodi M, **Rutherford T**, Schwartz PE, Abu-Khalaf M. (2010) Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma NEAGO 6/2010
49. Galper SL, Harrington, J, Ratner, E, Deng, Y, Zelterman, D, Hui, P, **Rutherford TJ**, Higgins SA. (2010) Postoperative vaginal brachytherapy alone (VB) provides equally effective treatment with less toxicity than external beam radiation and vaginal brachytherapy (EXT + VB) in the treatment of stage II endometrial adenocarcinoma. ASTRO 10/2010.
50. Bellone S, Cocco E, Varughese J, Buza N, Lin K, Bellone P, Todeschini P, Silasi D, Azodi M, Schwartz PE, **Rutherford TJ**, Carrara L, Tassi R, Pecorelli S, Lockwood C.J, Santin AD. (2011) Tissue Factor Expression in Ovarian Cancer: Implications for Immunotherapy

with hI-con1, a Factor VII-IgGFc Chimeric Protein Targeting Tissue Factor. SGI 58th Annual Meeting 3/2011.

51. Aghajanian C, Finkler NJ, **Rutherford T**, Smith DA, Yi J, Nycum LR, Sovak MA. (2011) A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). ASCO 6/2011.
52. Varughese J, Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Carrara L, Guzzo F, Siegel F, Silasi DA, Azodi M, **Rutherford T**, Pecorelli SL, Schwartz PE, Santin A. (2011) Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of *clostridium perfringens* enterotoxin. AACR 3/2011.
53. ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin A, Azodi M, Schwartz P, **Rutherford TJ**. (2011) The significance of perineural invasion in early-stage cervical cancer. Oral presentation 14th World Congress on Controversies in Obstetrics, Gynecology and Infertility. 9/2011
54. ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin A, Schwartz P, **Rutherford TJ**, Azodi M. (2011) Comparison between 155 cases of Robotic vs. 150 cases of open surgical staging for endometrial cancer. 9/2011.
55. Aghajanian C, Finkler N, **Rutherford T**, Teneriello M, Usain A, Sovak M, Nycum L. (2011) OCEANS, a phase III, multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer. Oral presentation at ESGO 9/2011
56. Roque DM, Ratner E, Silasi DA, Azodi M, Schwartz PE, **Rutherford TJ**, Santin A. (2012) Weekly Ixabepilone with and without concurrent bevacizumab in the treatment of recurrent endometrial cancer ASCO 6/2012.
57. Roque DM, Bellone S, Romani C, Buza N, Cocco E, Gasparrini S, Bignotti E, Ravaggi A, **Rutherford TJ**, Schwartz PE, Pecorelli S, Santin AD. (2012) Tubulin-B-III overexpression is a marker of sensitivity to epothilones in ovarian clear cell carcinoma. International Gynecologic Cancer Society (Vancouver 10/2012).
58. Roque DM, Bellone S, Buza N, Cocco E, Gasparrini S, **Rutherford TJ**, Schwartz PE, Santin AD. (2012) Tubulin-B-III overexpression by uterine serous papillary carcinomas is a marker for poor overall survival, paclitaxel resistance, and sensitivity to epothilones. 14th International Gynecologic Cancer Society (Vancouver 10/2012).
59. Roque DM, **Rutherford TJ**, Santin A. (2012) Increased Tubulin-B-III expression in serous cancers following paclitaxel administration: Implications for mechanisms of recurrent disease. 14th Biennial Meeting of the International Gynecologic Cancer Society – Plenary Presentation (Vancouver 10/2012)
60. Roque DM, Bellone S, Buza N, Romani C, Cocco E, Gasparrini S, Bignotti E, Ravaggi A, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Pecorelli S, Santin A. (2012) Class

III beta-tubulin overexpression in ovarian clear cell carcinoma is a marker of poor overall survival after Platinum/Taxane Chemotherapy and concurrent sensitivity to Patupilone. (IGCS 2012).

61. Roque D, Buza N, Glasgow M, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Santin A. (2013) Class III Beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. (SGO 2013).
62. Roque D, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Santin A. (2013) Weekly ixabepilone with and without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial cancer and ovarian cancers: an institutional experience. (NEAGO 2013).
63. **Rutherford T**, Orr J, Grendys E, Edwards R, Krivak T, Holloway R, Moore R, Puls L, Tilmanns T, Schink J, Brower S, Tian C, Herzog T. (2013) A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer (WAGO 2013)
64. Black J, Yoo N, **Rutherford T**, Tavassoli F, Ratner E, Azodi M, Silasi D, Buza N, Santin A, Schwartz P. (2013) Presentation and management of borderline ovarian tumors; Should mucinous tumors be managed differently. (SGO 2013)
65. Erekson E, Martin D, Fried T, **Rutherford T**, Strohhahn K, Bynum J. (2014) Frailty, cognitive impairment, and functional disability in older women seeking treatment for pelvic floor disorders. (American Geriatric Society May 2014)
66. Roque D, Varughese J, English D, Gressel G, Lundsberg M, Ratner E, Silasi D, Azodi M, **Rutherford T**, Santin A, Schwartz P. (2014) Treatment of Uterine Carcinosarcoma with Cisplatin + Ifosfamide, Paclitaxel + Ifosfamide, or Carboplatin + Paclitaxel. (SGI 2014)
67. Roque D, Schwab C, English D, Ratner E, Silasi D, Azodi M, **Rutherford T**, Schwartz P, Santin A. (2014) Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience. (SGO 2014)
68. Cocco E, Gasparini S, Shapiro E, Schwab C, Bellone S, Bortolomai I, Lopez S, Sumi N, Bonazzoli E, Nicoletti R, Deng Y, Saltzman W, Zeiss C, Silasi D, **Rutherford T**, Schwartz P, Santin, A. (2014) Optical fluorescence Imaging Using *Clostridium Perfringens* Enterotoxin Carboxy-terminal Fragment (c-CPE) to Target Metastatic Chemotherapy-Resistant Human Ovarian Cancer in Xenograft Mouse Models. (AACR 2014)
69. Schwab et al. (2015) Neratinib, an irreversible ErbB receptor tyrosine Kinase inhibitor, shows efficacy in the treatment of Her2 amplified carcinosarcoma in vitro and in vivo. (SGO 2015)
70. Black, J. et al. (2015) Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma. (SGO 2015)

71. Lopez S, **Rutherford TJ**. (2015) Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations. (SGO – 2015)
72. Ishiguro K, Lin ZP, **Rutherford TJ**, Ratner ES. (2015) Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel. (SGO-2015)
73. Black J, Lopez S, Cocco E, Bellone S, Bonazzoli, E, Schwab C, English DP, Goedings, P, Beusker, P, Van Der Lee M, Timmers M, Dokter W, **Rutherford T**, Schwartz PE, Santin, AD. SYD985, a novel HER2-targeting antibody-drug conjugate, shows strong antitumor activity in primary Uterine serous Carcinoma cell lines with low (1+) and moderate (2+) HER2/Neu expression. (AACR 2015)
74. Seagle BL, Abdullah A, Panaelli E, Samuelson R, **Rutherford TJ**, Schwartz PE, Shahabi S. (2015) Association of Nuclear Grade and Lymphovascular Space Invasion in Stage I Endometrial Endometrioid Adenocarcinomas. (ASCO 2015)
75. Seagle BL, Abdullah A, Panaelli E, Samuelson R, **Rutherford TJ**, Schwartz PE, Shahabi S. (2015) Role of nuclear grade in offering adjuvant vaginal brachytherapy in stage I endometrial cancers. (ASCO 2015)
76. Seagle B, Abdullah A, **Rutherford T**, Samuelson R, Shahabi S. (2015) Body mass index among women with endometrial cancer. (Neago 2015)
77. Kakar F, Fairbarn M, Zuckerman R, VanCott C, **Rutherford T**. (2016) Ovarian cancer use of HIPEC. (Neago 2016)

INVITED SPEAKER/OUTREACH SURGICAL MISSIONS

Shaanxi University of Chinese Medicine (5/2009) The role of neoadjuvant chemotherapy in the management of ovarian cancer / surgery

Jamaica – PRN – surgery 2009

Tri-state Medical Conference (2/10) Detection and screening of ovarian cancer

Shaanxi University of Chinese Medicine (4/2010) Modern Management of endometrial cancer / surgery

Jamaica – PRN – surgery 2010

Tri-State Medical Conference (2/11) Management of Placenta Percreta

Shaanxi University of Chinese Medicine (5/2011) Ovarian cancer: Detection, treatment and understanding Recurrence / surgery

Second Affiliated Hospital of Medical College of Xi'an Jiaotong University (5/2011) Ovarian cancer: Detection, treatment and understanding recurrence / surgery

Jamaica – PRN – surgery 2011

Tri-state Medical conference (2/2012) Surgical management of vulvar carcinoma

Shaanxi University of Chinese Medicine (4/2012) Vulvar Disease: Preinvasive and invasive identification and management / surgery

Second Affiliated Hospital of Medical College of Xi'an Jiaotong University (4/2012) Vulvar Disease: Preinvasive and invasive identification and management / surgery

Tomsk Medical Center (2012) Lecturer and surgery

Beijing Obstetrical and Gynecology Society (4/2012) Prevention and management of surgical adhesions

Beijing Obstetrical and Gynecology Society (4/2012) Ovarian cancer: Detection, treatment and understanding recurrence

SGO 2013 Late breaking data from a prospective multi-institutional trial evaluating the clinical relevance of a chemoresponse assay for treatment of patients with recurrent ovarian cancer

Shaanxi University of Chinese Medicine (2013) Uterine serous carcinoma – Is it really just a uterine cancer? / surgery

Jamaica – PRN – surgery 2013

Tomsk Medical Center (August 2013) Management and controversies in endometrial cancer/surgery

Jamaica – PRN – surgery 2014

Grand Rounds – Norwalk Hospital (April 2015)

Origin of ovarian cancer – Tampa General Hospital (April 2016)

The Forest or the Trees – No such thing as ovarian cancer – Hylton lecture – Roanoke College (November 2017)

Grand Rounds – University of Indiana – What is the role of cytoreductive surgery and HIPEC (5/8/19)

SGO Toronto 2020 – Preliminary prospective quality of life and clinical outcomes with an opiate restrictive enhanced recovery protocol in a gynecologic oncology population (March 2020)

PROTOCOLS / GRANTS

A study of Phenoxodiol in patients with recurrent ovarian, fallopian and primary peritoneal cancer that is resistant to second line chemotherapy

Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant

Principal Investigator: Thomas Rutherford, M.D., Ph.D.

Study Sponsor: Marshall Edwards Pty Limited \$837,545.00

A Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination with Docetaxel versus Docetaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy

Principal Investigator: Thomas J. Rutherford, M.D.

Study Sponsor: Marshall Edwards Pty Limited \$554,775.00

PT-301, A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc.

ChemoResponse Assay in Patients with Recurrent epithelial ovarian, Peritoneal or fallopian tube cancer

Principal Investigator: Thomas J. Rutherford, MD, PhD

Study Sponsor: Precision Therapeutics, Inc. \$93,600.00

Protocol AF4095g:

A Phase II, Multicenter, Randomized, Blinded Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma

Principal Investigator: Thomas J. Rutherford M.D.

Study Sponsor: Genentech, Inc.

Ovature Trial:

A Multi-Center, Multi-National, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-resistant or Platinum refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Platinum Therapy

Principal Investigator: Thomas J. Rutherford, M.D., Ph.D.

Study Sponsor: Marshall Edwards Pty Limited

A Phase II Study of AP23573:

A mTOR inhibitor, in female Adult Patients with recurrent of persistent endometrial cancer

CO-Investigator: Thomas J. Rutherford, M.D.

Study Sponsor: ARIAD Pharmaceuticals, Inc.

MyD88 bearing tumors in immune regulation and chemo-resistance;

ID#: R01-CA127913

Principle Investigator: Gil Mor M.D.

Co-Investigator: Thomas J Rutherford M.D., Ph.D.

Study Sponsor NCI: 2008 – 2013

Total Cost \$2,068,021 Direct Cost per year \$250,000

Apoptosis and cancer

NCI; ID# R01 CA97237-01

Principle Investigator: Gil Mor M.D.

Co-Investigator: Thomas J. Rutherford Ph.D., M.D.

Study Sponsor NCI: 2007 – 2012

Total Cost \$1,571,380 Direct Cost per year \$190,000

Ovarian cancer prevention and early detection program

ID#: 1H75DP001824-01

Principle Investigator: Thomas J Rutherford Ph.D., M.D.

Study Sponsor: CDC; National Center for Chronic Disease Prevention and Health Promotion

Total Cost \$286,899.00

YALE COMMITTEES

9/95-1/96 Subcommittee on Patient Care Evaluation
9/95-6/96 Communication Task Force
11/95 Oncology Clinical Practice Council
6/96-12/96 Clinical Studies Group
6/96-12/03 Protocol Review Committee
9/96-6/97 OR clinical pathways committee
9/98-1/2015 Clinic Chief, Division of Gynecologic Oncology
6/99 YFP Contracting Committee
11/00-11/01 IPA Board of Directors
2/04-1/2015 Fellowship Director, Division of Gynecologic Oncology
9/08-1/2015 Chairman, OR laser committee

Editorial Board Editor
The Scientific World Journal
Andrology & Gynecology

